The biopharma sector is experiencing a resurgence in mergers and acquisitions, with the first quarter marking the strongest period for such deals since 2020, according to a June 17 report from PwC. The firm predicts that large pharmaceutical companies will continue to focus on acquiring smaller firms with specialized scientific expertise rather than pursuing larger transformative deals.
“BioPharma M&A has entered a new phase driven less by scale and more by precision science. We expect M&A to remain strong through year-end as large caps close LOE [loss of exclusivity] gaps with high-conviction science across cardiometabolic, CNS, immunology, and oncology,” Roel van den Akker, principal and US Pharmaceutical & Life Sciences Deals Leader at PwC, said in a prepared statement.
PwC’s mid-year outlook highlights that nearly every major pharmaceutical company has completed at least one deal in the past 12 months. This trend reflects an urgency among these companies as they approach significant patent expirations that could impact business models. “After sitting out the first half of the decade and only making smaller deals, large pharmaceutical players are digging into their deep pockets to offset the estimated $300B+ of branded pharma revenue exposed to LOE this decade,” PwC wrote.
Recent deals have largely focused on small bolt-on acquisitions and mid-cap biotech firms working in differentiated science areas such as GLP-1 expansion, next-generation modalities like RNA technologies, antibody-drug conjugates (ADCs), and gene editing. The report also notes that artificial intelligence is increasingly important both as an investment rationale and for driving efficiencies within acquired pipelines: “AI’s growing ability to deliver efficiencies and synergies autonomously now rivals the benefits that large-scale M&A traditionally delivered.”
The analysis further observes continued dealmaking interest from U.S. and European pharmas in China—particularly within oncology, immunology, and metabolic disease—despite added geopolitical complexity. While initial public offerings have seen some record-setting debuts recently, many biotechs may be better suited for acquisition due to requirements for significant clinical proof before going public.
Private equity investors are also showing increased interest in life sciences transactions. According to PwC, “Capital and appetite are abundant. The scarce resource is differentiated assets with near-term commercial potential in the right therapeutic areas.”
